Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Third Harmonic Bio, Inc. (THRD)
NASDAQ:THRD
RESEARCH TOOLSreports
Third Harmonic Bio, Inc. (THRD) Stock Price & Analysis
15 Followers
THRD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.72 - $16.94
Previous Close$12.89
Volume50.24K
Average Volume (3M)135.42K
Market Cap
$527.84M
Enterprise Value$262.72M
Total Cash (Recent Filing)$269.07M
Total Debt (Recent Filing)$3.95M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Aug 08, 2024EPS Estimate
-$0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.74
Shares Outstanding40,949,463
10 Day Avg. Volume74,864
30 Day Avg. Volume135,419
Standard Deviation0.26
R-Squared0.25
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.88
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-22.60
P/FCF Ratio145.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-13.49
Forecast
1Y Price Target
$20.50Price Target Upside67.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Third Harmonic Bio, Inc. News
PremiumCompany Announcements
Third Harmonic Bio Announces Executive Changes and Voting Results
PremiumCompany Announcements
Third Harmonic Bio Releases New Corporate Presentation
Bulls Say, Bears Say
Bulls Say
Innovation And DevelopmentTHRD brought forward a next-gen compound, THB335 that avoids the issue and recently entered Ph1.
Market OpportunityCSU represents a large commercial opportunity with 400K patients in the US remaining uncontrolled on standard of care high dose antihistamines.
Unique PositioningTHRD is the only oral wild-type KIT pure play, with potential first-in-class positioning.
Bears Say
Financial PerformanceTHRD reported a Q4 net loss of $6.8MM.
Product DevelopmentTHRD discontinued development of first-gen small molecule THB001 following the observation of liver toxicity in a Ph1b CIndU study.
Safety ConcernsThe Phase 1b cold urticaria study with THB001 was discontinued following the observation of asymptomatic liver transaminases in two of five patients.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
THRD FAQ
What was Third Harmonic Bio, Inc.’s price range in the past 12 months?
Third Harmonic Bio, Inc. lowest stock price was $4.72 and its highest was $16.94 in the past 12 months.
What is Third Harmonic Bio, Inc.’s market cap?
Currently, no data Available
When is Third Harmonic Bio, Inc.’s upcoming earnings report date?
Third Harmonic Bio, Inc.’s upcoming earnings report date is Aug 08, 2024 which is in 36 days.
How were Third Harmonic Bio, Inc.’s earnings last quarter?
Third Harmonic Bio, Inc. released its earnings results on May 15, 2024. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.31 by $0.11.
Is Third Harmonic Bio, Inc. overvalued?
According to Wall Street analysts Third Harmonic Bio, Inc.’s price is currently Undervalued.
Does Third Harmonic Bio, Inc. pay dividends?
Third Harmonic Bio, Inc. does not currently pay dividends.
What is Third Harmonic Bio, Inc.’s EPS estimate?
Third Harmonic Bio, Inc.’s EPS estimate is -$0.29.
How many shares outstanding does Third Harmonic Bio, Inc. have?
Third Harmonic Bio, Inc. has 40,949,463 shares outstanding.
What happened to Third Harmonic Bio, Inc.’s price movement after its last earnings report?
Third Harmonic Bio, Inc. reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.31. Following the earnings report the stock price went up 0.077%.
Which hedge fund is a major shareholder of Third Harmonic Bio, Inc.?
Among the largest hedge funds holding Third Harmonic Bio, Inc.’s share is RA Capital Management. It holds Third Harmonic Bio, Inc.’s shares valued at 19M.
---
Third Harmonic Bio, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.50 (67.48% Upside)
$20.50 (67.48% Upside)
Blogger Sentiment
Bullish
THRD Sentiment 100%
Sector Average 72%
Sector Average 72%
Technicals
SMA
Positive
20 days / 200 days
Momentum
167.98%
12-Months-Change
Fundamentals
Return on Equity
-10.84%
Trailing 12-Months
Asset Growth
-7.16%
Trailing 12-Months
Company Description
Third Harmonic Bio, Inc.
Third Harmonic Bio Inc is a clinical-stage company developing a novel oral approach to the treatment of severe allergy and inflammation. The company's lead product candidate, THB001, is a highly selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival.
---
THRD Stock 12 Month Forecast
Average Price Target
$20.50
▲(67.48% Upside)
Technical Analysis
Best Analysts Covering THRD
1 Year
1 Year Success Rate
3/5 ratings generated profit
1 Year Average Return
+21.94%
assigned a buy rating 2 months ago
Copying Joseph Thome's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +21.94% per trade.
---